More recently, it has been reported a patient with metastatic poorly differentiated thyroid carcinoma with an EGFR mutation who responded to treatment with the selective EGFR TKI (tyrosine kinase inhibitor) erlotinib, strongly suggesting the importance of EGFR as therapeutic target in DePTC [44]. Here, EGFR is linked to differentiated thyroid carcinoma.